hESC-derived Olig2+ progenitors generate a subtype of astroglia with protective effects against ischaemic brain injury

Peng Jiang, Chen Chen, Ruimin Wang, Olga V. Chechneva, Seung Hyuk Chung, Mahendra S. Rao, David E. Pleasure, Ying Liu, Quanguang Zhang, Wenbin Deng

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Human pluripotent stem cells (hPSCs) have been differentiated to astroglia, but the utilization of hPSC-derived astroglia as cell therapy for neurological diseases has not been well studied. Astroglia are heterogeneous, and not all astroglia are equivalent in promoting neural repair. A prerequisite for cell therapy is to derive defined cell populations with superior therapeutic effects. Here we use an Olig2-GFP human embryonic stem cell (hESC) reporter to demonstrate that hESC-derived Olig2+ progenitors generate a subtype of previously uncharacterized astroglia (Olig2PC-Astros). These Olig2PC-Astros differ substantially from astroglia differentiated from Olig2-negative hESC-derived neural progenitor cells (NPC-Astros), particularly in their neuroprotective properties. When grafted into brains subjected to global ischaemia, Olig2PC-Astros exhibit superior neuroprotective effects and improved behavioural outcome compared to NPC-Astros. Thus, this new paradigm of human astroglial differentiation is useful for studying the heterogeneity of human astroglia, and the unique Olig2PC-Astros may constitute a new cell therapy for treating cerebral ischaemia and other neurological diseases.

Original languageEnglish (US)
Article number2196
JournalNature communications
Volume4
DOIs
StatePublished - Dec 1 2013

Fingerprint

brain damage
stem cells
Stem cells
Astrocytes
Brain Injuries
Brain
ischemia
therapy
Cell- and Tissue-Based Therapy
cells
Pluripotent Stem Cells
brain
Neuroprotective Agents
Therapeutic Uses
Human Embryonic Stem Cells
Brain Ischemia
Repair
Stem Cells
Ischemia
Cells

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

hESC-derived Olig2+ progenitors generate a subtype of astroglia with protective effects against ischaemic brain injury. / Jiang, Peng; Chen, Chen; Wang, Ruimin; Chechneva, Olga V.; Chung, Seung Hyuk; Rao, Mahendra S.; Pleasure, David E.; Liu, Ying; Zhang, Quanguang; Deng, Wenbin.

In: Nature communications, Vol. 4, 2196, 01.12.2013.

Research output: Contribution to journalArticle

Jiang, P, Chen, C, Wang, R, Chechneva, OV, Chung, SH, Rao, MS, Pleasure, DE, Liu, Y, Zhang, Q & Deng, W 2013, 'hESC-derived Olig2+ progenitors generate a subtype of astroglia with protective effects against ischaemic brain injury', Nature communications, vol. 4, 2196. https://doi.org/10.1038/ncomms3196
Jiang, Peng ; Chen, Chen ; Wang, Ruimin ; Chechneva, Olga V. ; Chung, Seung Hyuk ; Rao, Mahendra S. ; Pleasure, David E. ; Liu, Ying ; Zhang, Quanguang ; Deng, Wenbin. / hESC-derived Olig2+ progenitors generate a subtype of astroglia with protective effects against ischaemic brain injury. In: Nature communications. 2013 ; Vol. 4.
@article{b594202c1bfe4598af8616a9253f3931,
title = "hESC-derived Olig2+ progenitors generate a subtype of astroglia with protective effects against ischaemic brain injury",
abstract = "Human pluripotent stem cells (hPSCs) have been differentiated to astroglia, but the utilization of hPSC-derived astroglia as cell therapy for neurological diseases has not been well studied. Astroglia are heterogeneous, and not all astroglia are equivalent in promoting neural repair. A prerequisite for cell therapy is to derive defined cell populations with superior therapeutic effects. Here we use an Olig2-GFP human embryonic stem cell (hESC) reporter to demonstrate that hESC-derived Olig2+ progenitors generate a subtype of previously uncharacterized astroglia (Olig2PC-Astros). These Olig2PC-Astros differ substantially from astroglia differentiated from Olig2-negative hESC-derived neural progenitor cells (NPC-Astros), particularly in their neuroprotective properties. When grafted into brains subjected to global ischaemia, Olig2PC-Astros exhibit superior neuroprotective effects and improved behavioural outcome compared to NPC-Astros. Thus, this new paradigm of human astroglial differentiation is useful for studying the heterogeneity of human astroglia, and the unique Olig2PC-Astros may constitute a new cell therapy for treating cerebral ischaemia and other neurological diseases.",
author = "Peng Jiang and Chen Chen and Ruimin Wang and Chechneva, {Olga V.} and Chung, {Seung Hyuk} and Rao, {Mahendra S.} and Pleasure, {David E.} and Ying Liu and Quanguang Zhang and Wenbin Deng",
year = "2013",
month = "12",
day = "1",
doi = "10.1038/ncomms3196",
language = "English (US)",
volume = "4",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - hESC-derived Olig2+ progenitors generate a subtype of astroglia with protective effects against ischaemic brain injury

AU - Jiang, Peng

AU - Chen, Chen

AU - Wang, Ruimin

AU - Chechneva, Olga V.

AU - Chung, Seung Hyuk

AU - Rao, Mahendra S.

AU - Pleasure, David E.

AU - Liu, Ying

AU - Zhang, Quanguang

AU - Deng, Wenbin

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Human pluripotent stem cells (hPSCs) have been differentiated to astroglia, but the utilization of hPSC-derived astroglia as cell therapy for neurological diseases has not been well studied. Astroglia are heterogeneous, and not all astroglia are equivalent in promoting neural repair. A prerequisite for cell therapy is to derive defined cell populations with superior therapeutic effects. Here we use an Olig2-GFP human embryonic stem cell (hESC) reporter to demonstrate that hESC-derived Olig2+ progenitors generate a subtype of previously uncharacterized astroglia (Olig2PC-Astros). These Olig2PC-Astros differ substantially from astroglia differentiated from Olig2-negative hESC-derived neural progenitor cells (NPC-Astros), particularly in their neuroprotective properties. When grafted into brains subjected to global ischaemia, Olig2PC-Astros exhibit superior neuroprotective effects and improved behavioural outcome compared to NPC-Astros. Thus, this new paradigm of human astroglial differentiation is useful for studying the heterogeneity of human astroglia, and the unique Olig2PC-Astros may constitute a new cell therapy for treating cerebral ischaemia and other neurological diseases.

AB - Human pluripotent stem cells (hPSCs) have been differentiated to astroglia, but the utilization of hPSC-derived astroglia as cell therapy for neurological diseases has not been well studied. Astroglia are heterogeneous, and not all astroglia are equivalent in promoting neural repair. A prerequisite for cell therapy is to derive defined cell populations with superior therapeutic effects. Here we use an Olig2-GFP human embryonic stem cell (hESC) reporter to demonstrate that hESC-derived Olig2+ progenitors generate a subtype of previously uncharacterized astroglia (Olig2PC-Astros). These Olig2PC-Astros differ substantially from astroglia differentiated from Olig2-negative hESC-derived neural progenitor cells (NPC-Astros), particularly in their neuroprotective properties. When grafted into brains subjected to global ischaemia, Olig2PC-Astros exhibit superior neuroprotective effects and improved behavioural outcome compared to NPC-Astros. Thus, this new paradigm of human astroglial differentiation is useful for studying the heterogeneity of human astroglia, and the unique Olig2PC-Astros may constitute a new cell therapy for treating cerebral ischaemia and other neurological diseases.

UR - http://www.scopus.com/inward/record.url?scp=84893156687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893156687&partnerID=8YFLogxK

U2 - 10.1038/ncomms3196

DO - 10.1038/ncomms3196

M3 - Article

C2 - 23880652

AN - SCOPUS:84893156687

VL - 4

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 2196

ER -